US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.06 against a street estimate of 0.17 — a miss of 64.7%.
Analysts rate Dr. Reddy’s Laboratories Ltd ADR a buy (2 buy, 1 hold, 1 sell out of 4) with an average price target of $13.40.
| Fund | Stake |
|---|---|
| Robeco Institutional Asset Management BV | 2.16% |
| BlackRock Inc | 1.39% |
| Royal Bank of Canada | 1.20% |
| Morgan Stanley - Brokerage Accounts | 1.13% |
| Aikya Investment Management Ltd | 1.02% |
| Renaissance Technologies Corp | 0.94% |
| Dimensional Fund Advisors, Inc. | 0.64% |
| JPMorgan Chase & Co | 0.53% |
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.08 / share ex-date Jul 24, 2026 · pay Aug 5, 2026 | 2026-07-24 |
| Dividend | $0.06 / share ex-date Jul 9, 2026 | 2026-07-09 |
| Split | 5 : 1 effective Nov 5, 2024 | 2024-11-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dr. Reddy’s Laboratories Ltd ADR — free to start.
Google PlayApp StoreData updated 2026-09-18.